MX2013010160A - Formulacion que comprende derivado de fenilaminopirimidina como agente activo. - Google Patents

Formulacion que comprende derivado de fenilaminopirimidina como agente activo.

Info

Publication number
MX2013010160A
MX2013010160A MX2013010160A MX2013010160A MX2013010160A MX 2013010160 A MX2013010160 A MX 2013010160A MX 2013010160 A MX2013010160 A MX 2013010160A MX 2013010160 A MX2013010160 A MX 2013010160A MX 2013010160 A MX2013010160 A MX 2013010160A
Authority
MX
Mexico
Prior art keywords
formulation
nrc
active agent
phenylaminopyrimidine derivative
bcr
Prior art date
Application number
MX2013010160A
Other languages
English (en)
Other versions
MX339130B (es
Inventor
Durga Maheswari Parvataneni
Siddhartha Yedluri
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013010160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MX2013010160A publication Critical patent/MX2013010160A/es
Publication of MX339130B publication Critical patent/MX339130B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una formulación farmacéutica oral que contiene una cantidad efectiva de NRCAN-019 incluyendo sus sales farmacéuticamente aceptables y polimorfos tales como Forma I, Forma II y Forma III del mismo para mejorar la biodisponibilidad destinada para auto-emulsificación al hacer contacto con el fluido gastrointestinal. La invención también se refiere a un procedimiento para la preparación de solución oral que contiene NRC-AN-019 en una concentración efectiva para la mejor terapia contra leucemia mieloide crónica como inhibidor de •tirosina quinasa de BCR-ABL y contra otros tumores tales como cáncer de cabeza y cuello, cáncer de próstata y similares.
MX2013010160A 2011-03-07 2011-08-10 Formulacion que comprende derivado de fenilaminopirimidina como agente activo. MX339130B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (2)

Publication Number Publication Date
MX2013010160A true MX2013010160A (es) 2013-12-06
MX339130B MX339130B (es) 2016-05-13

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010160A MX339130B (es) 2011-03-07 2011-08-10 Formulacion que comprende derivado de fenilaminopirimidina como agente activo.

Country Status (32)

Country Link
US (1) US9895367B2 (es)
EP (1) EP2683381B1 (es)
JP (1) JP5788534B2 (es)
KR (1) KR101767296B1 (es)
CN (1) CN103561742B (es)
AP (1) AP4076A (es)
AU (1) AU2011361921B2 (es)
BR (1) BR112013022930A2 (es)
CA (1) CA2829015C (es)
CO (1) CO6811851A2 (es)
CY (1) CY1116968T1 (es)
DK (1) DK2683381T3 (es)
EA (1) EA024610B1 (es)
ES (1) ES2554927T3 (es)
GB (1) GB2488788B (es)
GE (1) GEP20156410B (es)
HR (1) HRP20151382T1 (es)
HU (1) HUE025562T2 (es)
IL (1) IL228218A (es)
MA (1) MA35088B1 (es)
MX (1) MX339130B (es)
MY (1) MY158693A (es)
NZ (1) NZ614903A (es)
PL (1) PL2683381T3 (es)
PT (1) PT2683381E (es)
RS (1) RS54420B1 (es)
SG (1) SG193349A1 (es)
SI (1) SI2683381T1 (es)
SM (1) SMT201500235B (es)
UA (1) UA111074C2 (es)
WO (1) WO2012120328A1 (es)
ZA (1) ZA201306643B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122592C2 (uk) * 2015-12-18 2020-12-10 Натко Фарма Лтд Фармацевтичні композиції, які містять похідні феніламінопіримідину
EP3397242B1 (en) * 2015-12-29 2021-02-03 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
MA51999B1 (fr) 2018-03-14 2024-02-29 Kandy Therapeutics Ltd Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3.
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
WO1999006024A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6248354B1 (en) 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
US20080103305A1 (en) * 2006-10-26 2008-05-01 Macdonald Peter Process for the preparation of imatinib
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
KR101697363B1 (ko) * 2007-04-30 2017-01-17 인터자인 테크놀로지스, 인코포레이티드 소수성 제제를 캡슐화하기 위해 사용되는 혼합 입체화학을 가지는 혼성 블록 공중합체 미셀
US8067422B2 (en) * 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
JP2011513380A (ja) 2008-03-04 2011-04-28 ナトコ ファーマ リミテッド フェニルアミノピリミジン誘導体の結晶型
JP5791500B2 (ja) * 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤

Also Published As

Publication number Publication date
UA111074C2 (uk) 2016-03-25
MA35088B1 (fr) 2014-05-02
CN103561742B (zh) 2016-04-27
MX339130B (es) 2016-05-13
NZ614903A (en) 2014-08-29
HUE025562T2 (en) 2016-03-29
GB2488788A (en) 2012-09-12
BR112013022930A2 (pt) 2016-12-06
KR101767296B1 (ko) 2017-08-10
AU2011361921A2 (en) 2014-10-30
AU2011361921A1 (en) 2013-09-26
RS54420B1 (en) 2016-04-28
AU2011361921B2 (en) 2016-06-09
SG193349A1 (en) 2013-10-30
EA201391280A1 (ru) 2014-02-28
CA2829015A1 (en) 2012-09-13
CA2829015C (en) 2018-01-02
GEP20156410B (en) 2015-12-10
CY1116968T1 (el) 2017-04-05
CN103561742A (zh) 2014-02-05
PT2683381E (pt) 2015-11-02
ZA201306643B (en) 2014-11-26
WO2012120328A1 (en) 2012-09-13
CO6811851A2 (es) 2013-12-16
SMT201500235B (it) 2015-10-30
JP2014507463A (ja) 2014-03-27
US20130338180A1 (en) 2013-12-19
EP2683381B1 (en) 2015-09-16
KR20140016926A (ko) 2014-02-10
SI2683381T1 (sl) 2016-01-29
EP2683381A1 (en) 2014-01-15
HRP20151382T1 (hr) 2016-02-12
AP4076A (en) 2017-03-23
US9895367B2 (en) 2018-02-20
GB201103860D0 (en) 2011-04-20
ES2554927T3 (es) 2015-12-28
EA024610B1 (ru) 2016-10-31
AP2013007128A0 (en) 2013-09-30
IL228218A (en) 2016-06-30
MY158693A (en) 2016-11-15
GB2488788B (en) 2013-07-10
DK2683381T3 (en) 2015-12-21
JP5788534B2 (ja) 2015-09-30
PL2683381T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
NZ630457A (en) Compounds useful as inhibitors of atr kinase
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2013010160A (es) Formulacion que comprende derivado de fenilaminopirimidina como agente activo.
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
MY149731A (en) Compounds
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
ECSP13013006A (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
MX365702B (es) Inhibidores de pirazolil quinoxalina cinasa.
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
MX2013012588A (es) Inhibidores de cinasa.
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX371119B (es) Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
PH12018501292A1 (en) Pharmaceutical compositions comprising phenylaminopyridine derviative
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
WO2013055913A3 (en) Pgam1 inhibitors and methods related thereto
JP2014530181A5 (es)

Legal Events

Date Code Title Description
FG Grant or registration